% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • zake1 zake1 Mar 26, 2014 8:00 AM Flag

    Piper says don't panic..from this morning

    Insmed met 'much more meaningful' secondary endpoint, says Piper Jaffray
    Piper Jaffray says Insmed's Phase 2 Study of Arikayce for nontuberculous mycobacteria met the "much more meaningful and clinically relevant" secondary endpoint of culture conversion while missing the less clinically relevant primary endpoint of sputum density. Piper says the drug works and thinks the stock could end up staying close to where it is currently given the split decision on endpoints. The firm reiterates an Overweight rating on Insmed

14.04-0.03(-0.21%)Oct 21 4:00 PMEDT